Related Experiment Video

Updated: Jul 7, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K

Therapeutic Monoclonal Antibodies against Cancer: Present and Future

Marisa Delgado1, Jose A Garcia-Sanz1

  • 1Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), 28040 Madrid, Spain.

Cells
|December 22, 2023
PubMed

Insights

Monoclonal antibodies are revolutionizing cancer treatment, enabling precision medicine. A strategic shift is needed to broaden their use by exploring new antibody types and engineering for enhanced efficacy against various diseases.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) are pivotal in modern cancer therapy, with 91 currently in clinical use, often combined with chemotherapy or other immunotherapies like immune checkpoint inhibitors.
  • These advancements have driven the paradigm of personalized or precision medicine in oncology.
  • Despite successes, challenges like drug resistance necessitate further innovation.

Purpose of the Study:

  • To propose a strategic shift in therapeutic antibody development beyond current IgG-based approaches.
  • To explore the potential of alternative antibody classes (IgA, IgE, IgM) and engineered antibody variants for broader therapeutic applications.
  • To discuss the advantages and disadvantages of these strategic changes using cancer therapeutics as a model.

Main Methods:

  • Review and strategic analysis of therapeutic antibody development.
  • Discussion of engineering strategies to enhance antibody half-life and effector functions.
  • Consideration of agonistic antibodies and alternative antibody isotypes (IgA, IgE, IgM).

Main Results:

  • Current therapeutic antibodies, primarily IgG, are effective but face limitations.
  • Exploring diverse antibody classes and engineering novel antibody formats can overcome resistance and enhance efficacy.
  • Strategic implementation of these changes is crucial for expanding precision medicine.

Conclusions:

  • A paradigm shift in antibody development is required to fully realize the potential of precision medicine.
  • Incorporating diverse antibody classes and advanced engineering offers a promising future for antibody therapeutics.
  • The proposed strategies are applicable to antibody therapies for infectious and autoimmune diseases as well as cancer.
Keywords:
bioinformaticscancer database analysescancer treatmenttherapeutic antibodiestransmembrane proteins

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
370
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K